ArticleDocumenta ophthalmologica. Advances in ophthalmology2021
Assessment of the safety of intravitreal injection of metoprolol tartrate in rabbits.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Efficacy of the novel MIGS implant Wistend compared to Kahook Dual Blade in the treatment of experimental ocular hypertension in rabbits.Scientific reports · 2025Article
- Effectiveness and biocompatibility of a novel Schlemm's canal microstent for glaucoma management.Scientific reports · 2024Article
- Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial.International journal of retina and vitreous · 2023Article
- β-Adrenoreceptors as Therapeutic Targets for Ocular Tumors and Other Eye Diseases-Historical Aspects and Nowadays Understanding.International journal of molecular sciences · 2023Review
- Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation.Pharmaceutics · 2023Article
- Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.Documenta ophthalmologica. Advances in ophthalmology · 2022Article
- Alternative management of central serous chorioretinopathy using intravitreal metoprolol.International journal of retina and vitreous · 2022Article
- Anti-angiogenic activity and safety of intraocular application of triterpenes.Documenta ophthalmologica. Advances in ophthalmology · 2021Article
- Intravitreal metoprolol for circumscribed choroidal hemangiomas: a phase I clinical trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo verify the safety of different doses of intravitreal metoprolol tartrate (MT) after intravitreal injection in rabbit eyes.
methodsAnimals were randomly assigned into 2 groups: group I received 50 µg of MT and group II 100 µg of MT. A volume of 0.05 mL of the drug solution was administered through an intravitreal injection, while the control eyes received an equal volume of saline solution. Safety was assessed by clinical observation, electroretinography (ERG) and histological evaluation.
resultsNo evidence of clinical toxicity was observed. ERG waveforms from the MT treated eyes were similar to those recorded from the control eyes in dark-adapted state, amplitude and the implicit time are similar between the groups in light-adapted state, and their retinas had no signs of toxicity by histological evaluation 7 days after intravitreal injection.
conclusionsThe intravitreal use of metoprolol at 50 and 100 µg dosages does not cause short-term retinal toxicity in rabbits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.